Xolair(omalizumab): indicated to treat moderate-to-severe persistent asthma in patients 6 years old or older18 Fasenra (benralizumab), another monoclonal antibody against the IL-5 receptor19 Dupixent (dupilumab), indicated to treat moderate-to-severe eosinophilic asthma in patients 12 years old or...
hours; leukotriene receptor antagonists (LTRAs), such as montelukast or zafirlukast; slow-release theophylline; long-acting muscarinic receptor antagonists (LAMAs) such as tiotropium bromide or glycopyrronium bromide; with biologics such as omalizumab, mepolizumab, reslizumab, benralizumab, or ...